Furthermore, DNA-based vaccine candidates such as ADVAX may offer value economically, since these vaccines are relatively inexpensive and easy to manufacture, two characteristics that make them particularly appealing for use in the developing world.ADVAX will be administered with the Biojector??? 2000 needle-free injection system.